Skip to main content

Advertisement

Log in

Intensity of Follow-Up After Melanoma Surgery

  • Melanomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

This contemporary review of melanoma surveillance strategies seeks to help practitioners examine and improve their surveillance protocols based on the currently available data. In general, there is no definitive benefit from increased screening or more aggressive use of interval imaging. Low-intensity surveillance strategies do not appear to adversely affect patient outcomes and should be the preferred approach compared with high-intensity strategies for most melanoma patients. All surveillance programs should emphasize education in order to maximize the effectiveness of patient-based detection of recurrent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER website, April 2013.

  3. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294:1647–54.

    Article  CAS  PubMed  Google Scholar 

  4. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:395–407.

    CAS  PubMed  Google Scholar 

  5. Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer. 2000;88:1063–71.

    Article  CAS  PubMed  Google Scholar 

  6. Francken A, Bastiaannet E, Hoekstra H. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–21.

    Article  PubMed  Google Scholar 

  7. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62–70.

    Article  CAS  PubMed  Google Scholar 

  8. Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, et al. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol. 2010;17:2015–23.

    Article  PubMed  Google Scholar 

  9. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997;79:2361–70.

    Article  CAS  PubMed  Google Scholar 

  10. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer. 1999;86:2252–8.

    Article  CAS  PubMed  Google Scholar 

  11. Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–9.

    Article  PubMed  Google Scholar 

  12. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042–7.

    Article  PubMed  Google Scholar 

  13. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924–33.

    Article  PubMed  Google Scholar 

  14. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol). 1993;5:174–80.

    Article  CAS  PubMed  Google Scholar 

  15. Einwachter-Thompson J, MacKie RM. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Br J Dermatol. 2008;159:337–41.

    Article  CAS  PubMed  Google Scholar 

  16. Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 2011;29:4641–6.

    Article  PubMed  Google Scholar 

  17. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer. 1997;80:1052–64.

    Article  CAS  PubMed  Google Scholar 

  18. Leiter U, Marghoob AA, Lasithiotakis K, Eigentler TK, Meier F, Meisner C, et al. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res. 2009;19:50–7.

    Article  PubMed  Google Scholar 

  19. Morton RL, Craig JC, Thompson JF. The role of surveillance chest x-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol. 2009;16:571–7.

    Article  PubMed  Google Scholar 

  20. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129–42.

    Article  PubMed  Google Scholar 

  21. Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995;191:199–203.

    Article  CAS  PubMed  Google Scholar 

  22. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995;221:566–9 (discussion 569–71).

    Article  CAS  PubMed  Google Scholar 

  23. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703–5.

    Article  CAS  PubMed  Google Scholar 

  24. Moloney DM, Gordon DJ, Briggs JC, Rigby HS. Recurrence of thin melanoma: how effective is follow-up? Br J Plast Surg. 1996;49:409–13.

    Article  CAS  PubMed  Google Scholar 

  25. Sylaidis P, Gordon D, Rigby H, Kenealy J. Follow-up requirements for thick cutaneous melanoma. Br J Plast Surg. 1997;50:349–53.

    Article  CAS  PubMed  Google Scholar 

  26. Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol. 1998;5:54–63.

    Article  CAS  PubMed  Google Scholar 

  27. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140:249–54.

    Article  CAS  PubMed  Google Scholar 

  28. Johnson RC, Fenn NJ, Horgan K, Mansel RE. Follow-up of patients with a thin melanoma. Br J Surg. 1999;86:619–21.

    Article  CAS  PubMed  Google Scholar 

  29. Kittler H, Weitzdorfer R, Pehamberger H, Wolff K, Binder M. Compliance with follow-up and prognosis among patients with thin melanomas. Eur J Cancer. 2001;37:1504–9.

    Article  CAS  PubMed  Google Scholar 

  30. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients: monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528–35 (discussion 535–7).

    PubMed  Google Scholar 

  32. Schmid-Wendtner MH, Baumert J, Eberle J, Plewig G, Volkenandt M, Sander CA. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977–98. Br J Dermatol. 2003;149:788–93.

    Article  PubMed  Google Scholar 

  33. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg. 2008;95:1401–7.

    Article  CAS  PubMed  Google Scholar 

  34. Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG, et al. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol. 2008;15:2206–14.

    Article  PubMed  Google Scholar 

  35. Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16:941–7.

    Article  PubMed  Google Scholar 

Download references

Disclosure

The authors of this work have no conflicts of interest pertaining to this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sandra L. Wong MD, MS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scally, C.P., Wong, S.L. Intensity of Follow-Up After Melanoma Surgery. Ann Surg Oncol 21, 752–757 (2014). https://doi.org/10.1245/s10434-013-3295-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3295-9

Keywords

Navigation